Worldwide access to treatment for end-stage kidney disease: a systematic review

Thaminda Liyanage(The George Institute for Global Health), Vlado Perkovic(New South Wales Department of Health), Alan Cass(University of Sydney), Vivekanand Jha(The George Institute for Global Health), Ikechi G. Okpechi(University of Cape Town), Jicheng Lv(Ministry of Education of the People's Republic of China), Bruce Neal(UNSW Sydney), Martin Gallagher(The George Institute for Global Health), Sradha Kotwal(The George Institute for Global Health), Toshiharu Ninomiya(Kyushu University), John Knight(The George Institute for Global Health), Halle Marie Patrice(University of Douala), Amit X. Garg(Icahn School of Medicine at Mount Sinai), Ming‐Hui Zhao(Peking University), Anthony Rodgers(The George Institute for Global Health)
The Lancet
March 13, 2015
10.1016/s0140-6736(14)61601-9
Cited by 2,314

Related Papers

Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
|Journal of the American College of Cardiology|2020|11.1k
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
|The Lancet|2016|7.8k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k